AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 2 - (NewsRx.com & NewsRx.net) -- Researchers have demonstrated the feasibility of edible vaccine development.
According to recent research published in the journal Molecular Breeding, "Mannheimia haemolytica is the principal microorganism responsible for bovine pneumonic pasteurellosis, or shipping fever. We have previously expressed a fragment of leukotoxin, a major virulent factor of M. haemolytica A1, as a fusion protein with green fluorescent protein (GFP) in transgenic white clover and demonstrated that this antigen was immunogenic and elicited toxin neutralizing antibodies in rabbits."
"These previous results showed that using plants to produce M. haemolytica antigen for use as a vaccine against this disease is a viable strategy," said Raymond W. H. Lee and colleagues at the University of Guelph in Canada. "In this present study, we examined the stability of the truncated leukotoxin GFP-fusion protein (Lkt50-GFP) in field-grown transgenic white clover."
"Transgenic clover expressing Lkt50-GFP was clonally propagated and a confined field trial was established," reported the investigators. "Western immunoblotting showed that the level of Lkt50-GFP expression in field plants was the same as in transgenic plants ...
Source: HighBeam Research, Feasibility of edible vaccine development demonstrated.